IP Library Granted Patent US 10,308,720
Granted Patent B2
US 10,308,720 · App. 15/213,296 · Granted Jun 4, 2019

Multivalent and multispecific DR5-binding fusion proteins

Inventors: John C. Timmer (La Jolla, CA); Kyle S. Jones (La Jolla, CA); Amir S. Razai (La Jolla, CA); Abrahim Hussain (La Jolla, CA); Katelyn M. Willis (La Jolla, CA); Quinn Deveraux (La Jolla, CA); Brendan P. Eckelman (La Jolla, CA)
Assignee: Inhibrx, Inc.
C07K16/2878A61K2039/505C07K2317/22C07K2317/24C07K2317/33C07K2317/35C07K2317/567C07K2317/569C07K2317/73C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,308,720
App. No.
15/213,296
Granted
Jun 4, 2019
Kind
B2
Abstract

The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.

Claims (24)

1. An isolated polypeptide that binds death receptor 5 (DR5) and comprises a plurality of DR5 binding domains (DR5BDs), wherein each DR5BD is a VHH comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 128, a CDR2 comprising the amino acid sequence of SEQ ID NO: 131, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 130, and wherein adjacent DR5BDs are operably linked by an amino acid linker.

2. The isolated polypeptide of claim 1 , wherein the plurality of DR5BDs is two DR5BDs.

3. The isolated polypeptide of claim 1 , wherein the plurality of DR5BDs is four DR5BDs.

4. The isolated polypeptide of claim 1 , wherein the plurality of DR5BDs is six DR5BDs.

5. The isolated polypeptide of claim 1 , wherein each DR5BD comprises the amino acid sequence of SEQ ID NO: 87.

6. The isolated polypeptide of claim 2 , wherein each DR5BD comprises the amino acid sequence of SEQ ID NO: 87.

7. The isolated polypeptide of claim 3 , wherein each DR5BD comprises the amino acid sequence of SEQ ID NO: 87.

8. The isolated polypeptide of claim 4 , wherein each DR5BD comprises the amino acid sequence of SEQ ID NO: 87.

9. The isolated polypeptide of claim 3 , wherein the polypeptide is a homodimer of the structure: DR5BD-Linker-DR5BD-Linker-Hinge-Fc, where each DR5BD is a humanized VHH sequence.

10. The isolated polypeptide of claim 9 , wherein each DR5BD comprises the amino acid sequence of SEQ ID NO: 87.

11. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises an immunoglobulin hinge region and an immunoglobulin Fc region.

12. The isolated polypeptide of claim 11 , wherein the immunoglobulin hinge region comprises an amino acid sequence selected from EPKSSDKTHTCPPC (SEQ ID NO: 6), DKTHTCPPC (SEQ ID NO: 7), ESKYGPPCPPC (SEQ ID NO: 8).

13. The isolated polypeptide of claim 11 , wherein the immunoglobulin Fc region is an IgG1 Fc region, an IgG2 Fc region, an IgG3 Fc region, or an IgG1 Fc region.

14. The isolated polypeptide of claim 11 , wherein the immunoglobulin Fc region comprises an amino acid sequence selected from SEQ ID NOs: 1-5 or 127.

15. The isolated polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 113.

16. The isolated polypeptide of claim 15 , wherein the polypeptide is a homodimer of the amino acid sequence of SEQ ID NO: 113 fused to an Fc region polypeptide.

17. The isolated polypeptide of claim 1 , wherein each amino acid linker consists of 5-20 amino acids.

18. The isolated polypeptide of claim 17 , wherein each amino acid linker is composed predominantly of glycine and serine.

19. The isolated polypeptide of claim 18 , wherein each amino acid linker comprises an amino acid sequence selected from GGSGGS (SEQ ID NO: 11); GGSGGSGGS (SEQ ID NO: 12); GGSGGSGGSGGS (SEQ ID NO: 13); and GGSGGSGGSGGSGGS (SEQ ID NO: 14).

20. The isolated polypeptide of claim 10 , wherein each amino acid linker consists of 5-20 amino acids.

21. The isolated polypeptide of claim 20 , wherein each amino acid linker is composed predominantly of glycine and serine.

22. The isolated polypeptide of claim 21 , wherein each amino acid linker comprises an amino acid sequence selected from GGSGGS (SEQ ID NO: 11); GGSGGSGGS (SEQ ID NO: 12); GGSGGSGGSGGS (SEQ ID NO: 13); and GGSGGSGGSGGSGGS (SEQ ID NO: 14).

23. The isolated polypeptide of claim 1 , wherein each VHH is a humanized VHH.

24. An isolated polypeptide that binds death receptor 5 (DR5), wherein the polypeptide is a homodimer of the amino acid sequence of SEQ ID NO: 113 fused to an Fc region polypeptide of SEQ ID NO: 2.

Assignments (7)
SECURITY INTEREST Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0338 →
RELEASE OF SECURITY INTEREST Recorded Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
MERGER AND CHANGE OF NAME Recorded May 22, 2018
From: INHIBRX LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 046215/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2018
From: INHIBRX BIOPHARMA, LLP
To: INHIBRX LP
Reel/Frame 044762/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2016
From: TIMMER, JOHN C.; JONES, KYLE S.; RAZAI, AMIR S.; HUSSAIN, ABRAHIM; WILLIS, KATELYN M.; DEVERAUX, QUINN; ECKELMAN, BRENDAN P.
To: INHIBRX LP
Reel/Frame 040073/0748 →
Continuity (2)
Provisional Application 62193309 · Jul 16, 2015
Related Publication 20170015753A1 · Jan 19, 2017